US · Healthcare · Biotechnology
EPS came in at -0.30 against a street estimate of -0.34 — a beat of 11.8%.
Analysts rate Wave Life Sciences Ltd a strong buy (19 buy, 2 hold, 0 sell out of 21) with an average price target of $17.00.
CONFIDENT Wave reported strong clinical and partnership progress, with WVE-006 moving toward a single registrational trial and WVE-007 advancing across obesity treatment settings. Q3 FY26 Analysts focused on WVE-006’s trial design, approval endpoints, dosing and assay strategy, plus WVE-007’s weight-loss potential. Management emphasized the single-trial pathway, biomarker strategy and higher adiposity in Phase IIa. 2026-10-27…
Full summary in the app.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 13.69% |
| BlackRock Inc | 9.75% |
| GSK PLC | 9.26% |
| Maverick Capital Ltd | 5.22% |
| Driehaus Capital Management LLC | 2.76% |
| PRIMECAP Management Company | 2.72% |
| FMR Inc | 2.50% |
| 683 Capital Management LLC | 2.49% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines. It has not generated product revenue and co | 2026-10-27 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $13.2 million, compared with $7.6 million in Q3 2025; nine-month revenue was $53.676 million versus $25.482 mi | 2026-10-27 |
| Proxy statement · Q4 2026 EXECUTIVE PAY • CEO Paul B. Bolno, M.D., MBA’s total compensation and year-over-year change are not included in the provided excerpt. The excerpt onl | 2026-10-14 |
| Quarterly report · Q2 2026 WAVE LIFE SCIENCES LTD. - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $368.0 million cash + $122.6 million marketable securities = $490 | 2026-07-30 |
| Results announced · Q3 2026 WAVE LIFE SCIENCES LTD. - Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $490.6 million as of June | 2026-07-30 |
| Shareholder vote results · Q2 2026 WAVE LIFE SCIENCES LTD. – 8-K SUMMARY HEADLINE NUMBERS • Shareholder Vote Result: 155,190,836 shares voted in favor of redomiciliation scheme vs. 78 | 2026-06-26 |
| Reg FD disclosure · Q2 2026 WAVE LIFE SCIENCES LTD. - 8-K SUMMARY HEADLINE NUMBERS • Company: Wave Life Sciences Ltd., Singapore-incorporated biotech company • Trading Symbol: | 2026-05-18 |
| Proxy statement · Q2 2026 WAVE LIFE SCIENCES LTD. PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Vote Item: Approval of the Scheme of Arrangement to redomicil | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Wave Life Sciences Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.